Early Rewards for Careful Targeting in Oncology

Two early-stage cancer deals at the end of last year set a new high for European biotech pre-clinical deal dollars. They also highlighted the growing value, to Big Pharma and Big Biotech, of targeted, well-designed oncology leads, as progress in cancer therapeutics raises the hurdles for new products' potency and selectivity.